CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $167,852 | -33.6% | 3,698 | -17.9% | 0.00% | -100.0% |
| Q2 2023 | $252,967 | -60.1% | 4,506 | -71.1% | 0.00% | -66.7% |
| Q4 2022 | $633,896 | -87.6% | 15,594 | -80.9% | 0.00% | -93.0% |
| Q1 2022 | $5,122,000 | +139.9% | 81,592 | +189.6% | 0.04% | +168.8% |
| Q4 2021 | $2,135,000 | +16.4% | 28,178 | +148.8% | 0.02% | -23.8% |
| Q2 2021 | $1,834,000 | -16.5% | 11,327 | -21.0% | 0.02% | -32.3% |
| Q4 2020 | $2,196,000 | +50.4% | 14,344 | -17.8% | 0.03% | +47.6% |
| Q3 2020 | $1,460,000 | +79.6% | 17,455 | +30.8% | 0.02% | -19.2% |
| Q4 2019 | $813,000 | – | 13,348 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |